---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-006505"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T09:27:55.335555+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology closes $5.75M public offering to fund THIO trials and R&D

## Summary
- Gross proceeds of ~$5.75M from 2,555,500 shares at $2.25/share, including full over-allotment exercise.
- Net proceeds of ~$5.1M after underwriting discounts and expenses; intended for THIO trials and telomere compound development.
- Representative's warrants to purchase up to 127,775 shares at $2.8125/share, exercisable from Oct 2023 to Apr 2028.
- ThinkEquity acted as sole book-running manager for the offering.

## SEC filing metadata
- accession: 0001564590-23-006505
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/0001564590-23-006505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/maia-8k_20230424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-006505
- JSON: https://secwatch.observer/filing/0001564590-23-006505.json
- Plain text: https://secwatch.observer/filing/0001564590-23-006505.txt

## Key facts
- Material Agreements
  MAIA Biotechnology, Inc. entered into Underwriting Agreement with ThinkEquity LLC valued at aggregate net proceeds of approximately $5.1 million (effective 2023-04-24).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: ThinkEquity LLC
  - Value: aggregate net proceeds of approximately $5.1 million
  - Effective: 2023-04-24
  source text: On April 24, 2023, MAIA Biotechnology, Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC, as representative (the “Representative”) of the several underwriters identified therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023006505/0001564590-23-006505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.